Kenergy Responds To Shareholders

Tue Feb 5, 2013 11:36am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130205:nPnNE54625


FLEMINGTON, N.J.,  Feb. 5, 2013  /PRNewswire/ --  Ken Glynn, President and CEO
of GreenSmart Stores and Kenergy Scientific, Inc. (OTCQB: KNSC), received
numerous phone calls from shareholders and potential shareholders yesterday
after the press release indicating change of direction for the company. The
callers were told that, under SEC rules, the queries could not be answered
individually unless the information was already public. Ken responds here:

The current issued shares of common stock (Class A) is 1,803,407,529 (reported
at  1pm, on  Feb 4, 2013). Of these, more than 1.2 billion are restricted and
owned by Ken. He stated that he has not sold a single share of stock since he
took over more than 4 years ago and does not have any "friendly" people selling
stock for him.

Ken received only  $1,500  of his annual salary last year, averaging a pay of
less than  one cent  per hour! The unpaid salary is reported as accrued,
deferred salary and is convertible to stock in accordance with his employment
agreement on record with the SEC.

The company is not operated from anyone's basement. It occupies most of the
second floor at 6 Minneakoning Road in  Flemington, New Jersey  and shareholders
are welcome to visit by appointment.

The company will divest its eco-friendly business within the next four weeks.  

The patent application filed by Dr.  Alain Martin  and  Ken Glynn  as
co-inventors on biodegradable bandages using cell growth accelerators is pending
United States Patent Application No. 13/135,646, filed on  July 12, 2011.  This
can be confirmed by Publication No. 2013-0018334 A1 on  www.uspto.gov  the
official website of the US Patent & Trademark Office.  This invention is 2/3
owned by Kenergy Scientific, Inc. and 1/3 by Northcell Pharamceutical Inc.  Dr. 
Alain Martin  is CEO of Northcell Pharmaceutical Inc. and the inventor of the
improved Neosporin formulation.   

The Healthcare Division of the company is alive and well.  Ken has been working
for more than a year with consultants and co-inventors to firm up this side of
operations. A new Notice of Allowance was received and paid last week for the
cancer drug delivery series of inventions and another patent will issue. Ken has
quietly developed new inventions relating to upper respiratory and head injury
treatments.  Also,  Craig Smith, a pharma research consultant to the company,
has this morning agreed to represent Kenergy at the Third Annual Traumatic Brain
Injury Conference in early March in  Washington, D.C.  He will make a poster
presentation to the attendees on recent developments co-invented by Ken and
Craig in this field.   

This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements are based on the current
plans and expectations of management and are subject to a number of
uncertainties and risks that could significantly affect the company's current
plans and expectations, as well as future results of operations and financial
condition. A more extensive listing of risks and factors that may affect the
company's business prospects and cause actual results to differ materially from
those described in the forward-looking statements can be found in the reports
and other documents filed by the company with the Securities and Exchange
Commission. The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.  

Contact:. Kenergy Scientific, Inc.,  Ken Glynn, CEO and President, 908 788 0077.

SOURCE  Kenergy Scientific, Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.